EXETER, N.H.--(BUSINESS WIRE)--May 10, 2006--Bentley Pharmaceuticals, Inc. (NYSE: BNT - News), a specialty pharmaceutical company, today reported financial and operating results for the three months ended March 31, 2006. The Company continues to experience double-digit revenue growth in its specialty generics business, fueled by increased product sales and non-U.S. licensing and manufacturing agreements. The specialty generics business received 12 new product approvals in the first quarter of 2006. Bentley also more than doubled its investment in research and development programs for its drug delivery business as compared to the first quarter of 2005, with a specific emphasis on accelerating clinical research and development of an intranasal insulin product which is based on the Company’s proprietary drug delivery platform, CPE-215®.
